Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

Oncogene

Volumn 33, Issue 39, 2014, Pages 4735-4745

  Basova, P ^a   Pospisil, V ^a   Savvulidi, F ^a   Burda, P ^a   Vargova, K ^a   Stanek, L ^a   Dluhosova, M ^a   Kuzmova, E ^a   Jonasova, A ^a   Steidl, U ^b   Laslo, P ^c   Stopka, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

AML; Differentiation; Leukemia; microRNA; p53; PU.1

Indexed keywords

MICRORNA 155; PROTEIN MYB; PROTEIN P53; TRANSCRIPTION FACTOR PU 1; MICRORNA; MIRN155 MICRORNA, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE; ONCOPROTEIN; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; AGGRESSION; AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME MECHANISM; GENE DELETION; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE MYB; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGENITOR CELL LINE; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOLOGY; PROMOTER REGION; SPLEEN; TRANSCRIPTION INITIATION;

MURINAE; MUS;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVER; MICE; MICE, KNOCKOUT; MICRORNAS; ONCOGENE PROTEINS V-MYB; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; SPLEEN; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920839939     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.414     Document Type: Article

References (29)

1. Dahl R, Simon MC. The importance of PU.1 concentration in hematopoietic lineage commitment and maturation. Blood Cells Mol Dis 2003;31:229-233.
2. Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 1988;331:277-280.
3. Leddin M, Perrod C, Hoogenkamp M, Ghani S, Assi S, Heinz S et al. Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood 2011;117:2827-2838.
4. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004;36:624-630.
5. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007;27:847-859.
6. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008;205:585-594.
7. Ghani S, Riemke P, Schonheit J, Lenze D, Stumm J, Hoogenkamp M et al. Macrophage development from HSCs requires PU.1-coordinated microRNA expression. Blood 2011;118:2275-2284.
8. O'Connell RM, Zhao JL, Rao DS. MicroRNA function in myeloid biology. Blood 2011;118:2960-2969.
9. Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011;117:3816-3825.
10. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008;8:523-534.
11. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870.
12. Epstein CB, Attiyeh EF, Hobson DA, Silver AL, Broach JR, Levine AJ. p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors. Oncogene 1998;16:2115-2122.
13. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr. CA, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
14. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
15. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010;24:1389-1402.
16. Mannefeld M, Klassen E, Gaubatz S. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. Cancer Res 2009;69:4073-4080.
17. Tanikawa J, Ichikawa-Iwata E, Kanei-Ishii C, Nakai A, Matsuzawa S, Reed JC et al. p53 suppresses the c-Myb-induced activation of heat shock transcription factor 3. J Biol Chem 2000;275:15578-15585.
18. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-3157.
19. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008;22:1539-1541.
20. Nakano Y, Naoe T, Kiyoi H, Kitamura K, Minami S, Miyawaki S et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol 2000;65:23-31.
21. Noel G, De Koter RP, Wang Q, Hexley P, Ogle CK. Optimization and application of a flow cytometric PU.1 assay for murine immune cells. J Immunol Methods 2012;382:81-92.
22. Neiman PE, Elsaesser K, Loring G, Kimmel R. Myc oncogene-induced genomic instability: DNA palindromes in bursal lymphomagenesis. PLoS Genet 2008;4:e1000132.
23. Burda P, Curik N, Kokavec J, Basova P, Mikulenkova D, Skoultchi AI et al. PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation. Mol Cancer Res 2009;7:1693-1703.
24. Pattabiraman DR, Gonda TJ. Role and potential for therapeutic targeting of MYB in leukemia. Leukemia 2013;27:269-277.
25. Abbas HA, Pant V, Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle 2011;10:3257-3262.
26. Rao G, Rekhtman N, Cheng G, Krasikov T, Skoultchi AI. Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation. Oncogene 1997;14:123-131.
27. Pospisil V, Vargova K, Kokavec J, Rybarova J, Savvulidi F, Jonasova A et al. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J 2011;30:4450-4464.
28. Curik N, Burda P, Vargova K, Pospisil V, Belickova M, Vlckova P et al. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 2012;26:1804-1811.
29. Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011;153:24-32.